As the global population ages and various factors, including climate change and the pandemic, impact healthcare, the demand for numerous treatments, including low-molecular compounds, antibody therapies, and gene and cell therapies, has increased. It has increased the cost of the process and manufacturing engineering as organizations invest in technologies that ensure these therapies' secure and cost-effective production.
 
At Femtobiomed, we have been working on research and development for the past ten years, intending to deliver non-viral genetic materials to target cells. In early 2022, we launched our first commercial product, the CellShot device and platform. This technology allows for one-day, on-site treatment through the delivery of non-viral genetic material. It aims to simplify and automate the current manufacturing process for cell therapies. CellShot has the potential to enable small-scale, customized manufacturing to meet the growing demand for cell and gene therapies and minimize the vein-to-vein time.
 
In addition to our focus on developing and improving technology for the pharmaceutical market, we are also committed to sharing our knowledge and experience with institutions and organizations to advance the field of cell therapy. Our team is fully dedicated to meeting the technological needs of the pharmaceutical industry and improving treatment options for patients in need. Our dedication will ultimately reflect in the suitable and acceptable treatment options we provide.